GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Design Therapeutics Inc (NAS:DSGN) » Definitions » Price-to-Owner-Earnings

Design Therapeutics (Design Therapeutics) Price-to-Owner-Earnings : (As of May. 08, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Design Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-08), Design Therapeutics's share price is $4.69. Design Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Design Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


DSGN's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.95
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-08), Design Therapeutics's share price is $4.69. Design Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.20. Therefore, Design Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-08), Design Therapeutics's share price is $4.69. Design Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.20. Therefore, Design Therapeutics's PE Ratio without NRI for today is At Loss.


Design Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Design Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Design Therapeutics Price-to-Owner-Earnings Chart

Design Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - - -

Design Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Design Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Design Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Design Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Design Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Design Therapeutics's Price-to-Owner-Earnings falls into.



Design Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Design Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=4.69/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Design Therapeutics  (NAS:DSGN) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Design Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Design Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Design Therapeutics (Design Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6005 Hidden Valley Road, Suite 110, Carlsbad, CA, USA, 92011
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.
Executives
Rodney W Lappe director C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121
Deepa Prasad director C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT NC 27265
Arsani William director C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Joao Md Siffert director, officer: President and CEO 20 ENTERPRISE, SUITE 200, ALISO VIEJO CA 92656
Simeon George director, 10 percent owner 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Sr One Capital Fund I Aggregator Lp 10 percent owner C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Stella Xu director, 10 percent owner C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Julie Burgess officer: Chief Accounting Officer C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Dawn Giangiulio officer: Principal Accounting Officer C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Heather Behanna director C/O ENTASIS THERAPEUTICS HOLDINGS INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Pratik Shah director, officer: Executive Chairperson 3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037
Sean Jeffries officer: Chief Operating Officer C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Justin Thacker officer: Vice President, Finance C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Aseem Z. Ansari 10 percent owner C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011

Design Therapeutics (Design Therapeutics) Headlines